Personalized mRNA Vaccine for Pancreatic Cancer Enters Phase III Trials, China Leads Global Race
核心洞察
A personalized mRNA postoperative vaccine for pancreatic cancer (搜索), developed by Ruijin Hospital and an industry partner, has completed Phase I trials with results presented at ASCO 2026.
The vaccine aims to prevent recurrence after radical surgery, addressing the high relapse rate of approximately 50% within one year and 80% within five years.
Phase III clinical research is planned for completion by 2028, with the team committed to accelerating clinical translation for patient benefit.
A team led by Shen Baiyong, vice-president of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine (搜索), in collaboration with an industry partner, has developed a postoperative preventive vaccine for pancreatic cancer (搜索)—a breakthrough that positions China's personalized mRNA vaccine (搜索) among the global leaders in this field.
Phase I clinical trial results were recently presented at the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, marking what the team describes as a major global advancement in pancreatic cancer (搜索) therapy. The announcement was made during the 2026 academic conference of the Chinese Association of Pancreatology, hosted in Shanghai from Friday through Sunday, which brought together nearly 5,000 experts from around the world, including members of international pancreatic organizations.
The Unmet Need in Pancreatic Cancer (搜索)
Pancreatic cancer (搜索) carries a high malignancy and is notoriously prone to recurrence after surgery. Standard adjuvant chemotherapy remains the core treatment method following radical surgery, yet the recurrence rate remains alarmingly high—approximately 50 percent within one year and about 80 percent within five years. These stark statistics underscore the urgent need for novel therapeutic approaches that can meaningfully reduce postoperative recurrence.
A Personalized mRNA Approach
The vaccine developed by Shen Baiyong's team represents a personalized mRNA strategy tailored to individual patients following surgical resection. By leveraging messenger RNA technology, the vaccine is designed to train the patient's immune system to recognize and eliminate residual cancer cells, thereby reducing the likelihood of recurrence.
The Phase I results presented at ASCO have generated considerable interest within the global oncology community, positioning this candidate as one of the most advanced personalized cancer vaccines in development for pancreatic cancer (搜索).
Clinical Development Timeline
The team stated that clinical trials for the vaccine are ongoing, with plans to complete Phase III research by 2028. They emphasized their commitment to accelerating the clinical translation of the vaccine to benefit pancreatic cancer (搜索) patients as soon as possible. If successful, this would represent one of the first approved mRNA-based personalized cancer vaccines for a solid tumor with such a poor prognosis.
A Global Forum for Pancreatic Disease
The Shanghai conference served as the backdrop for this announcement, with nearly 1,300 academic submissions from nearly 200 medical institutions worldwide. Of these, 34 studies were selected for oral presentations, and 160 papers were showcased as posters, highlighting the latest research achievements in pancreatic diseases. Specialists from countries including the United States, Germany, Japan, and South Korea participated in international sessions conducted entirely in English.
The conference aimed to set a new direction for the high-quality development of pancreatic disease diagnosis and treatment in China, with discussions spanning multidisciplinary collaboration, industry-academia-research integration, talent cultivation, and targeted efforts on chronic diseases.